Drug Profile

Salmeterol inhalation aerosol - GlaxoSmithKline

Alternative Names: Salmeter; Serevent Inhalation Aerosol; Serevent Inhaler; Serevent MDI; Serobid

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Developer Allen & Hanburys; GlaxoSmithKline
Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
Mechanism of Action Beta 2 adrenergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Market Withdrawal Asthma; Bronchitis; Chronic obstructive pulmonary disease

Most Recent Events

19 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
03 Oct 2000 Launched for Bronchitis in New Zealand (Inhalation)
31 Dec 1999 Launched for Asthma in India (Inhalation)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com